Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study.
Mayer
A David
AD
Department of General Surgery, Queen Elizabeth Hospital, Birmingham B15 2TH, UK. david.mayer@university-b.wmids.nhs.uk
D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005060:Europe; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology*; D006085:Graft Survival / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D011183:Postoperative Complications / Q000453:epidemiology*; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus